EMP2 and endometrial cancer: For example, in the digital markers of patient samples (Table S4), the epithelial membrane protein 2 (EMP2) occurred in patient samples of colorectal cancer in response to 5-FU or oxaliplatin administration (Table S4), representing a novel therapeutic target for endometrial cancer stem cells,26,27 while the fact that the BAG cochaperone 3 (BAG3) occurred in colorectal cancer cell lines exposed to 5-FU or oxaliplatin correlates with apoptosis in treated colon cancer cell lines28 and chemoresistance.29